Chemical and structural modifications of RNAi therapeutics

Sook Hee Ku, Sung Duk Jo, Yeon Kyung Lee, Kwang Meyung Kim, Sun Hwa Kim

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Small interfering RNA (siRNA), a 21–23 nt double-stranded RNA responsible for post-transcriptional gene silencing, has attracted great interests as promising genomic drugs, due to its strong ability to silence target genes in a sequence-specific manner. Despite high silencing efficiency and on-target specificity, the clinical translation of siRNA has been hindered by its inherent features: poor intracellular delivery, limited blood stability, unpredictable immune responses and unwanted off-targeting effects. To overcome these hindrances, researchers have made various advances to modify siRNA itself and to improve its delivery. In this review paper, first we briefly discuss the innate properties and delivery barriers of siRNA. Then, we describe recent progress in (1) chemically and structurally modified siRNAs to solve their intrinsic problems and (2) siRNA delivery formulations including siRNA conjugates, polymerized siRNA, and nucleic acid-based nanoparticles to improve in vivo delivery.

Original languageEnglish
Pages (from-to)16-28
Number of pages13
JournalAdvanced Drug Delivery Reviews
Volume104
DOIs
Publication statusPublished - 2016 Jan 1
Externally publishedYes

Fingerprint

Small Interfering RNA
Double-Stranded RNA
RNA Interference
RNAi Therapeutics
Nanoparticles
Nucleic Acids
Research Personnel
Pharmaceutical Preparations
Genes

Keywords

  • Chemical modification
  • RNA interference
  • siRNA
  • siRNA delivery
  • Structural modification

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Chemical and structural modifications of RNAi therapeutics. / Ku, Sook Hee; Jo, Sung Duk; Lee, Yeon Kyung; Kim, Kwang Meyung; Kim, Sun Hwa.

In: Advanced Drug Delivery Reviews, Vol. 104, 01.01.2016, p. 16-28.

Research output: Contribution to journalReview article

Ku, Sook Hee ; Jo, Sung Duk ; Lee, Yeon Kyung ; Kim, Kwang Meyung ; Kim, Sun Hwa. / Chemical and structural modifications of RNAi therapeutics. In: Advanced Drug Delivery Reviews. 2016 ; Vol. 104. pp. 16-28.
@article{78fe04d007f8456083525a767adf30ae,
title = "Chemical and structural modifications of RNAi therapeutics",
abstract = "Small interfering RNA (siRNA), a 21–23 nt double-stranded RNA responsible for post-transcriptional gene silencing, has attracted great interests as promising genomic drugs, due to its strong ability to silence target genes in a sequence-specific manner. Despite high silencing efficiency and on-target specificity, the clinical translation of siRNA has been hindered by its inherent features: poor intracellular delivery, limited blood stability, unpredictable immune responses and unwanted off-targeting effects. To overcome these hindrances, researchers have made various advances to modify siRNA itself and to improve its delivery. In this review paper, first we briefly discuss the innate properties and delivery barriers of siRNA. Then, we describe recent progress in (1) chemically and structurally modified siRNAs to solve their intrinsic problems and (2) siRNA delivery formulations including siRNA conjugates, polymerized siRNA, and nucleic acid-based nanoparticles to improve in vivo delivery.",
keywords = "Chemical modification, RNA interference, siRNA, siRNA delivery, Structural modification",
author = "Ku, {Sook Hee} and Jo, {Sung Duk} and Lee, {Yeon Kyung} and Kim, {Kwang Meyung} and Kim, {Sun Hwa}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.addr.2015.10.015",
language = "English",
volume = "104",
pages = "16--28",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Chemical and structural modifications of RNAi therapeutics

AU - Ku, Sook Hee

AU - Jo, Sung Duk

AU - Lee, Yeon Kyung

AU - Kim, Kwang Meyung

AU - Kim, Sun Hwa

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Small interfering RNA (siRNA), a 21–23 nt double-stranded RNA responsible for post-transcriptional gene silencing, has attracted great interests as promising genomic drugs, due to its strong ability to silence target genes in a sequence-specific manner. Despite high silencing efficiency and on-target specificity, the clinical translation of siRNA has been hindered by its inherent features: poor intracellular delivery, limited blood stability, unpredictable immune responses and unwanted off-targeting effects. To overcome these hindrances, researchers have made various advances to modify siRNA itself and to improve its delivery. In this review paper, first we briefly discuss the innate properties and delivery barriers of siRNA. Then, we describe recent progress in (1) chemically and structurally modified siRNAs to solve their intrinsic problems and (2) siRNA delivery formulations including siRNA conjugates, polymerized siRNA, and nucleic acid-based nanoparticles to improve in vivo delivery.

AB - Small interfering RNA (siRNA), a 21–23 nt double-stranded RNA responsible for post-transcriptional gene silencing, has attracted great interests as promising genomic drugs, due to its strong ability to silence target genes in a sequence-specific manner. Despite high silencing efficiency and on-target specificity, the clinical translation of siRNA has been hindered by its inherent features: poor intracellular delivery, limited blood stability, unpredictable immune responses and unwanted off-targeting effects. To overcome these hindrances, researchers have made various advances to modify siRNA itself and to improve its delivery. In this review paper, first we briefly discuss the innate properties and delivery barriers of siRNA. Then, we describe recent progress in (1) chemically and structurally modified siRNAs to solve their intrinsic problems and (2) siRNA delivery formulations including siRNA conjugates, polymerized siRNA, and nucleic acid-based nanoparticles to improve in vivo delivery.

KW - Chemical modification

KW - RNA interference

KW - siRNA

KW - siRNA delivery

KW - Structural modification

UR - http://www.scopus.com/inward/record.url?scp=84957687437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957687437&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2015.10.015

DO - 10.1016/j.addr.2015.10.015

M3 - Review article

C2 - 26549145

AN - SCOPUS:84957687437

VL - 104

SP - 16

EP - 28

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -